Nordic Bioscience Welcomes Investment from KKR for Next Phase of Growth
KKR s investment will support Nordic Bioscience with commercialization and the global expansion of its R&D services, diagnostics platform, leading patent portfolio and drug development pipeline
Nordic Bioscience A/S, a Danish company and world leader in biomarker development, announced today the signing of an investment from KKR, a leading global investment firm. KKR will acquire a minority equity stake in Nordic Bioscience from existing shareholders and will support the company in accelerating its global growth.
Nordic Bioscience has world-leading knowledge and ownership of biomarkers, measurable indicators of biological change or response used for the development of diagnostic tools and identification of new drug candidates.
KKR Sells Five UK Student Accommodation Assets For £291m
Under KKR s ownership, the assets have been developed to meet growing demand for high-quality student accommodation in an underserved market
KKR, a leading global investment firm, today announced the sale of five major student housing developments across the UK to Greystar Real Estate Partners LLC, a global leader in the investment, development, and management of high-quality rental housing, for £291m.
The five Purpose Build Student Accommodation (PBSA) developments comprise a total of 2,163 units situated in London, Glasgow, Coventry and Bristol, four cities renowned for their higher education institutions. Four of the assets are operational for the 2020/21 academic year, while the asset in Bristol is under construction and due for occupancy in September 2021.
KKR Appoints Michael Small as Partner in European Credit & Markets Team
Appointment further demonstrates focus on scaling KKR s Private Credit business globally
KKR, a leading global investment firm, today announced the appointment of Michael Small as a Partner in KKR s European Credit Markets team. In his role, Michael will have certain origination, execution and fundraising responsibilities for KKR s Private Credit business and the broader Credit Markets platform. He will also help grow KKR s global mezzanine strategy. Michael will sit on several KKR Credit Investment Committees and will join the firm in mid-2021.
Michael will join KKR from Park Square Capital, where he was a Partner from its inception in 2004. At Park Square Capital, he was responsible for the sourcing and execution of Private Credit investments. Michael was a member of Park Square s Executive Committee and Investment Committee. Before joining Park Square, Michael was a Director in Dresdner s Principal Finance
(2)
Appointment further demonstrates focus on expanding the firm s presence in the Healthcare sector
KKR, a leading global investment firm, today announced the appointment of Giacomo Di Nepi as a Senior Advisor, effective immediately. In his role, Mr. Di Nepi will advise KKR on Healthcare investment opportunities and support existing portfolio companies.
Mr. Di Nepi brings nearly 40 years of global experience in the Healthcare sector. He began his career at McKinsey, followed by 11 years at Novartis where he held a number of executive roles, including CEO of Novartis Italy and Global Head of the Infectious Diseases, Transplantation, and Immunology Business Unit and member of the Global Pharma Executive Committee. He also served as CEO of Takeda Europe. In 2009 he launched the European operations of Intermune near Basel, with the company growing exponentially under his leadership until a USD 8.3bn exit to Roche in 2015. He subsequently became CEO of Polyphor, a Swiss biopharma com